Tag: Immunosuppressant

Methotrexate is a first-line treatment for many patients with rheumatoid arthritis [1.2.3]. This leads to a crucial question for patients and clinicians alike: is methotrexate considered an anti-inflammatory medication in the traditional sense? The answer is complex.

Initially developed as an antimalarial drug, hydroxychloroquine (brand name Plaquenil) is now widely used for its anti-inflammatory properties in autoimmune conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). For many patients, a key question arises: is hydroxychloroquine an immunosuppressant?

Affecting millions of adults, psoriasis is a chronic inflammatory skin condition. In many cases, it manifests as moderate to severe plaque psoriasis, a condition now treated effectively with the oral medication Deucravacitinib.

In severe inflammatory lung conditions, corticosteroids like prednisone are powerful immunosuppressants used to calm the body’s exaggerated immune response. So, what does prednisone do to your lungs? It works by reducing the inflammation and swelling that can constrict airways and impair normal respiratory function.

Reports from patients show that headaches and a feeling of 'methotrexate fog' are common side effects, typically occurring the day after a dose. Understanding **why does methotrexate cause headaches** is key to managing this and other related side effects.

Fingolimod, a medication for multiple sclerosis, has an average half-life of 6 to 9 days for both the parent drug and its active metabolite. This long half-life is crucial for understanding its steady-state blood concentrations and its persistent effects after treatment is stopped.

Ocrevus (ocrelizumab) is a CD20-directed cytolytic antibody used to treat relapsing or primary progressive forms of multiple sclerosis in adults [1.7.1]. Because it works by weakening your immune system, understanding **what to avoid while on Ocrevus** is crucial for your safety and treatment success.

An estimated 2.9 million people live with multiple sclerosis (MS) worldwide, many of whom rely on disease-modifying therapies. This raises a critical question for one such treatment: **Is Ocrevus a hazardous drug?** The answer involves understanding its classification, risks, and handling protocols.

Approved by the FDA in 2017, Ocrevus (ocrelizumab) was the first disease-modifying therapy for primary progressive multiple sclerosis (PPMS) [1.10.2]. A common question is, **does Ocrevus weaken the immune system?** The short answer is yes, by design.

Originally approved for non-Hodgkin's lymphoma, rituximab is increasingly used for autoimmune diseases, but is rituximab considered an immunosuppressant? The answer lies in its targeted B-cell depletion mechanism, which directly impacts a core component of the immune system.